Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Hildesheim

Showing results (1-10 of 360) with videos related to

Pageof 36
Sort By:
American Journal of Epidemiology|December 21, 2012
Invited commentary: Epstein-Barr virus-based screening for the early detection of nasopharyngeal carcinoma: a new frontierAllan Hildesheim
The Journal of Infectious Diseases|November 17, 2007
Human papillomavirus vaccine should be given before sexual debut for maximum benefitAllan Hildesheim, Rolando Herrero
Frontiers in Genetics|August 23, 2021
Association Between Human Leukocyte Antigen Class I and II Diversity and Non-virus-associated Solid TumorsZhiwei Liu, Allan Hildesheim
Journal of the National Cancer Institute. Monographs|June 17, 2003
Chapter 5: Viral and host factors in human papillomavirus persistence and progressionSophia S Wang, Allan Hildesheim
Seminars in Cancer Biology|February 4, 2012
Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011: Rosetta Stone for NPC: genetics, viral infection, and other environmental factorsAllan Hildesheim, Cheng-Ping Wang
American Journal of Epidemiology|August 30, 2014
Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literatureAnna E Coghill, Allan Hildesheim
Virus Research|November 26, 2002
Host and viral genetics and risk of cervical cancer: a reviewAllan Hildesheim, Sophia S Wang
Nature Reviews. Cancer|November 2, 2004
Opportunities for cancer epidemiology in developing countriesTanuja Rastogi, Allan Hildesheim, Rashmi Sinha
Journal of the National Cancer Institute|March 2, 2006
Etiology and prevention of cervical adenocarcinomasAllan Hildesheim, Amy Berrington de González
The Lancet. Oncology|May 7, 2015
Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridgingDouglas R Lowy, Rolando Herrero, Allan Hildesheim, et al.
Pageof 36

Showing results (1-10 of 360) with videos related to

Sort By:
Pageof 36
American Journal of Epidemiology|December 21, 2012
Invited commentary: Epstein-Barr virus-based screening for the early detection of nasopharyngeal carcinoma: a new frontierAllan Hildesheim
The Journal of Infectious Diseases|November 17, 2007
Human papillomavirus vaccine should be given before sexual debut for maximum benefitAllan Hildesheim, Rolando Herrero
Frontiers in Genetics|August 23, 2021
Association Between Human Leukocyte Antigen Class I and II Diversity and Non-virus-associated Solid TumorsZhiwei Liu, Allan Hildesheim
Journal of the National Cancer Institute. Monographs|June 17, 2003
Chapter 5: Viral and host factors in human papillomavirus persistence and progressionSophia S Wang, Allan Hildesheim
Seminars in Cancer Biology|February 4, 2012
Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011: Rosetta Stone for NPC: genetics, viral infection, and other environmental factorsAllan Hildesheim, Cheng-Ping Wang
American Journal of Epidemiology|August 30, 2014
Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literatureAnna E Coghill, Allan Hildesheim
Virus Research|November 26, 2002
Host and viral genetics and risk of cervical cancer: a reviewAllan Hildesheim, Sophia S Wang
Nature Reviews. Cancer|November 2, 2004
Opportunities for cancer epidemiology in developing countriesTanuja Rastogi, Allan Hildesheim, Rashmi Sinha
Journal of the National Cancer Institute|March 2, 2006
Etiology and prevention of cervical adenocarcinomasAllan Hildesheim, Amy Berrington de González
The Lancet. Oncology|May 7, 2015
Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridgingDouglas R Lowy, Rolando Herrero, Allan Hildesheim, et al.
Pageof 36